MS Pharma Partners With Mabxience For Bevacizumab In MENA Region
Follows Agreement With Alvion For Rosuvastatin/Ezetimibe In MENA
Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.
